AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NeurAxis, Inc.

$5.74 +$1.28 (+28.70%)
AMEX · 11 Sep 2026 20:00 UTC
Previous Close
$5.69
Day Range
$5.64$5.77
Year Range
$2.21$9.33
Market Cap
71.62M
AVG Volume
117.9K
Trailing/Forward PE
-7.45/-
PEG ratio
0.12
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
New York Stock Exchange ArcaUS
Revenue (USD) · TTM
02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q25.32M
26 Q14.28M
25 Q43.57M
25 Q33.36M
25 Q23.22M
25 Q12.93M
24 Q42.69M
24 Q32.46M
24 Q22.27M
24 Q12.3M
Net Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-7.87M
26 Q1-7.28M
25 Q4-7.8M
25 Q3-7.54M
25 Q2-7.17M
25 Q1-8.4M
24 Q4-8.24M
24 Q3-12.11M
24 Q2-18.98M
24 Q1-18.29M
Operating Income (USD) · TTM
-10M-7.5M-5M-2.5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-7.68M
26 Q1-7.28M
25 Q4-7.83M
25 Q3-7.58M
25 Q2-7.13M
25 Q1-7.62M
24 Q4-7.16M
24 Q3-7.31M
24 Q2-8.68M
24 Q1-7.6M
EBITDA (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-7.5M
26 Q1-7.12M
25 Q4-7.67M
25 Q3-7.45M
25 Q2-7.01M
25 Q1-8.11M
24 Q4-7.9M
24 Q3-11.74M
24 Q2-17.29M
24 Q1-15.67M
Cash Flows (USD) · TTM
-10M-7.5M-5M-2.5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-5.63M
26 Q1-6.07M
25 Q4-6.46M
25 Q3-6.28M
25 Q2-6.25M
25 Q1-6.4M
24 Q4-6.13M
24 Q3-7.01M
24 Q2-8.44M
24 Q1-7.44M
EPS (USD) · TTM
-3-2-1024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.77
26 Q1-0.8
25 Q4-0.95
25 Q3-1.03
25 Q2-1.04
25 Q1-1.24
24 Q4-1.23
24 Q3-1.83
24 Q2-2.98
24 Q1-2.93
Expenses (USD) · TTM
05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q212.24M
26 Q110.93M
25 Q410.87M
25 Q310.44M
25 Q29.89M
25 Q110.17M
24 Q49.52M
24 Q39.5M
24 Q210.71M
24 Q19.65M
Shares Outstanding · TTM
-2M-1M01M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
NRXS Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-1.29M
26 Q1-819.93K
25 Q4-596.31K
25 Q3-513.23K
25 Q2-624.66K
25 Q1-1.23M
24 Q4-1.4M
24 Q3469.88K
24 Q2741.62K
24 Q11.52M
Employee Count
0102030202320242025
NRXS Employee Count by quarter
PeriodEmployee Count
202524
202421
202319
Free Cash Flow Yield
-60%-40%-20%0%med -27.74%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NRXS Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-8.1%
Sep 26-7.8%
Aug 26-7.75%
Aug 26-7.56%
Aug 26-7.38%
Aug 26-7.82%
Jul 26-8.87%
Jul 26-8.16%
Jul 26-8.22%
Jul 26-7.77%
Jul 26-7.86%
Jun 26-7.63%
Jun 26-7.76%
Jun 26-8.28%
Jun 26-8.11%
May 26-7.48%
May 26-7.52%
May 26-7.05%
May 26-8.68%
May 26-8.81%
Apr 26-9.05%
Apr 26-9.86%
Apr 26-10.4%
Apr 26-9.82%
Mar 26-10.31%
Mar 26-9.34%
Mar 26-9.27%
Mar 26-11.14%
Feb 26-10.6%
Feb 26-11.5%
Feb 26-12.95%
Feb 26-14.62%
Jan 26-15.03%
Jan 26-13.09%
Jan 26-13.92%
Jan 26-13.09%
Jan 26-14.26%
Dec 25-16.22%
Dec 25-19.75%
Dec 25-24%
Dec 25-23.82%
Nov 25-22.88%
Nov 25-24.27%
Nov 25-27.18%
Nov 25-28.89%
Oct 25-26.98%
Oct 25-21.02%
Oct 25-24.22%
Oct 25-24.62%
Oct 25-23.07%
Sep 25-24.54%
Sep 25-28.89%
Sep 25-30.32%
Sep 25-30.19%
Aug 25-28.89%
Aug 25-29.71%
Aug 25-30.45%
Aug 25-34.86%
Aug 25-34.3%
Jul 25-30.96%
Jul 25-32.73%
Jul 25-35.73%
Jul 25-33.24%
Jun 25-34.58%
Jun 25-33.76%
Jun 25-37.45%
Jun 25-32.86%
May 25-31.41%
May 25-28.3%
May 25-38.12%
May 25-44.27%
May 25-38.16%
Apr 25-36.29%
Apr 25-55.34%
Apr 25-49.46%
Apr 25-47.86%
Mar 25-42.16%
Mar 25-38.33%
Mar 25-46.52%
Mar 25-45.88%
Feb 25-46.09%
Feb 25-43.5%
Feb 25-41.69%
Feb 25-39.48%
Jan 25-40.19%
Jan 25-32.21%
Jan 25-35.25%
Jan 25-40.35%
Jan 25-41.52%
Dec 24-41.35%
Dec 24-41.87%
Dec 24-40.51%
Dec 24-37.35%
Nov 24-33.8%
Nov 24-39.96%
Nov 24-38.69%
Nov 24-50.78%
Nov 24-47.06%
Oct 24-41.31%
Oct 24-40.36%
Price to Sales
0510152025med 7.97Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NRXS Price to Sales by quarter
PeriodPrice to Sales
Sep 2613.09
Sep 2613.59
Aug 2613.68
Aug 2614.02
Aug 2614.36
Aug 2618.13
Jul 2615.98
Jul 2617.39
Jul 2617.26
Jul 2618.26
Jul 2618.05
Jun 2618.59
Jun 2618.28
Jun 2617.13
Jun 2617.49
May 2618.95
May 2618.87
May 2620.12
May 2620.87
May 2620.56
Apr 2620
Apr 2618.37
Apr 2617.41
Apr 2618.45
Mar 2617.56
Mar 2619.39
Mar 2620.15
Mar 2616.78
Feb 2617.63
Feb 2616.25
Feb 2614.42
Feb 2612.78
Jan 2612.43
Jan 2614.28
Jan 2613.43
Jan 2614.28
Jan 2613.1
Dec 2511.52
Dec 259.46
Dec 257.79
Dec 257.84
Nov 258.17
Nov 257.7
Nov 256.87
Nov 256.73
Oct 257.2
Oct 259.24
Oct 258.02
Oct 257.89
Oct 258.42
Sep 257.92
Sep 256.73
Sep 256.41
Sep 256.44
Aug 256.73
Aug 256.54
Aug 256.38
Aug 256.26
Aug 256.36
Jul 257.04
Jul 256.66
Jul 256.1
Jul 256.56
Jun 256.31
Jun 256.46
Jun 255.82
Jun 256.64
May 256.94
May 257.71
May 255.72
May 255.15
May 255.98
Apr 256.29
Apr 254.12
Apr 254.61
Apr 254.77
Mar 255.41
Mar 255.95
Mar 256.14
Mar 256.22
Feb 256.2
Feb 256.56
Feb 256.85
Feb 257.23
Jan 257.1
Jan 258.87
Jan 258.1
Jan 257.08
Jan 256.88
Dec 246.91
Dec 246.82
Dec 247.05
Dec 247.64
Nov 248.45
Nov 249.31
Nov 249.62
Nov 247.33
Nov 247.91
Oct 249.01
Oct 249.22
Price to Book
0255075100med 13.61Apr 25Jul 25Oct 25Jan 26Mar 26Jun 26Sep 26
NRXS Price to Book by quarter
PeriodPrice to Book
Sep 2610.33
Sep 2610.73
Aug 2610.8
Aug 2611.07
Aug 2611.34
Aug 2613.51
Jul 2611.91
Jul 2612.95
Jul 2612.86
Jul 2613.6
Jul 2613.45
Jun 2613.85
Jun 2613.62
Jun 2612.76
Jun 2613.03
May 2614.11
May 2614.06
May 2614.99
May 2621.91
May 2621.59
Apr 2621
Apr 2619.29
Apr 2618.28
Apr 2619.37
Mar 2618.44
Mar 2620.36
Mar 2629.66
Mar 2624.68
Feb 2625.94
Feb 2623.91
Feb 2621.23
Feb 2618.81
Jan 2618.29
Jan 2621.01
Jan 2619.76
Jan 2621.01
Jan 2619.28
Dec 2516.95
Dec 2513.92
Dec 2511.46
Dec 2511.54
Nov 2512.02
Nov 2511.33
Nov 2510.12
Nov 255.09
Oct 255.45
Oct 256.99
Oct 256.07
Oct 255.97
Oct 256.37
Sep 255.99
Sep 255.09
Sep 254.85
Sep 254.87
Aug 255.09
Aug 254.95
Aug 254.83
Aug 2571.03
Aug 2572.19
Jul 2579.98
Jul 2575.65
Jul 2569.3
Jul 2574.5
Jun 2571.61
Jun 2573.34
Jun 2566.12
Jun 2575.36
May 2578.83
May 2587.49
May 2564.97
May 256.69
May 257.76
Apr 258.16
Apr 255.35
Apr 255.99
Apr 256.19
Mar 257.03
Mar 257.73
NeurAxis, Inc.
NRXS
Stockpicker

Video analysis: NRXS

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NRXS

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

zacks.com · 12 Sep 2026

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

KODK and NRXS are worth watching for their growth.

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

zacks.com · 14 Aug 2026

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

seekingalpha.com · 11 Aug 2026

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis Expands Payer Coverage with New Policies

globenewswire.com · 4 Aug 2026

NeurAxis Expands Payer Coverage with New Policies

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

globenewswire.com · 28 Jul 2026

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.